1563 related articles for article (PubMed ID: 9765382)
1. A third-generation lentivirus vector with a conditional packaging system.
Dull T; Zufferey R; Kelly M; Mandel RJ; Nguyen M; Trono D; Naldini L
J Virol; 1998 Nov; 72(11):8463-71. PubMed ID: 9765382
[TBL] [Abstract][Full Text] [Related]
2. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
4. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
5. A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.
Srinivasakumar N; Schuening FG
J Virol; 1999 Nov; 73(11):9589-98. PubMed ID: 10516068
[TBL] [Abstract][Full Text] [Related]
6. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
7. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system.
Pandya S; Boris-Lawrie K; Leung NJ; Akkina R; Planelles V
Hum Gene Ther; 2001 May; 12(7):847-57. PubMed ID: 11339901
[TBL] [Abstract][Full Text] [Related]
8. Rev-dependent lentiviral expression vector.
Wu Y; Beddall MH; Marsh JW
Retrovirology; 2007 Feb; 4():12. PubMed ID: 17286866
[TBL] [Abstract][Full Text] [Related]
9. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.
Zufferey R; Dull T; Mandel RJ; Bukovsky A; Quiroz D; Naldini L; Trono D
J Virol; 1998 Dec; 72(12):9873-80. PubMed ID: 9811723
[TBL] [Abstract][Full Text] [Related]
10. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.
Kim VN; Mitrophanous K; Kingsman SM; Kingsman AJ
J Virol; 1998 Jan; 72(1):811-6. PubMed ID: 9420292
[TBL] [Abstract][Full Text] [Related]
11. Safety considerations in vector development.
Kappes JC; Wu X
Somat Cell Mol Genet; 2001 Nov; 26(1-6):147-58. PubMed ID: 12465466
[TBL] [Abstract][Full Text] [Related]
12. Helper plasmids for production of HIV-1-derived vectors.
Fuller M; Anson DS
Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
[TBL] [Abstract][Full Text] [Related]
13. Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems.
Matukonis M; Li M; Molina RP; Paszkiet B; Kaleko M; Luo T
Hum Gene Ther; 2002 Jul; 13(11):1293-303. PubMed ID: 12162812
[TBL] [Abstract][Full Text] [Related]
14. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
16. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.
Molina RP; Ye HQ; Brady J; Zhang J; Zimmerman H; Kaleko M; Luo T
Hum Gene Ther; 2004 Sep; 15(9):865-77. PubMed ID: 15353041
[TBL] [Abstract][Full Text] [Related]
17. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.
Mochizuki H; Schwartz JP; Tanaka K; Brady RO; Reiser J
J Virol; 1998 Nov; 72(11):8873-83. PubMed ID: 9765432
[TBL] [Abstract][Full Text] [Related]
18. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.
Bahner I; Zhou C; Yu XJ; Hao QL; Guatelli JC; Kohn DB
J Virol; 1993 Jun; 67(6):3199-207. PubMed ID: 8388497
[TBL] [Abstract][Full Text] [Related]
19. Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.
Mendenhall A; Lesnik J; Mukherjee C; Antes T; Sengupta R
J Vis Exp; 2012 Apr; (62):e3171. PubMed ID: 22508377
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir.
Mukhtar M; Duke H; BouHamdan M; Pomerantz RJ
Hum Gene Ther; 2000 Jan; 11(2):347-59. PubMed ID: 10680847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
